PHASE II TRIAL OF INTRAVENOUSLY ADMINISTERED AMD3100 (PLERIXAFOR) FOR STEM CELL MOBILIZATION IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION FOLLOWING A LENALIDOMIDE BASED INITIAL THERAPY
Biology of Blood and Marrow Transplantation (Impact Factor: 3.94). 02/2012; 18:S247-S247. DOI: 10.1016/j.bbmt.2011.12.129
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.